Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 1:18 PM
Ignite Modification Date:
2025-12-26 @ 1:18 PM
NCT ID:
NCT02678806
Eligibility Criteria:
Inclusion Criteria:
1. Patients were pathologically diagnosed as BCLC-A stage hepatocellular carcinomas, liver function were Child-Pugh class A or liver function changed from class B to class A after short-term liver treatment, PS scored 0-1, and accepted hepatocellular carcinomas resection (R0 resection).
2. No recurrence was found within 3-4 weeks after surgery.
3. pathologically confirmed as narrow margin (the closest distance from margin to tumor capsule (\<1 cm) and microvascular invasion was found in tumor capsule and adjacent tissues junction (material selection and pathological diagnosis were based on "Standardization pathology Guide of primary liver cancer 2015 edition" ).
4. Postoperative radiotherapy was the only combination therapy within one month after surgery.
5. Radiation range was margin radiation along and/or joint portal vessels radiotherapy.
6. No lymph node and distant metastasis before surgery.
Exclusion Criteria:
1. Patients were pathologically diagnosed as BCLC-B, C, D stage hepatocellular carcinomas, liver function were Child-Pugh class C, PS scored ≥2. Or primary liver cancer patients were pathologically diagnosed as cholangiocarcinoma or mixed type liver cancer. Or patients did not accept hepatectomy.
2. Patients received transcatheter arterial chemoembolization, chemotherapy, targeted medicine or other anti-cancer therapy before surgery.
3. Recurrence was found within 3-4 weeks after surgery.
4. Postoperative adjuvant therapy included treatment other than radiotherapy within one month after surgery.
5. Radiation range involved lymph node other than portal vein area.
6. Lymph node and distant metastasis were diagnosed before surgery.
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT02678806
Study Brief:
Protocol Section:
NCT02678806